This page shows the latest Tafinlar news and features for those working in and with pharma, biotech and healthcare.
Novartis scores but Roche misses in melanoma trials. Phase III trial combo success for Tafinlar/Mekinist “unprecedented”. ... A phase III trial of Novartis Tafinlar and Mekinist has confirmed the potential of the pair in the post-surgical treatment
Novartis gets lung cancer OK for Tafinlar/Mekinist combo. It can now be used to treat BRAF V600E-positive NSCLC patients in Europe. ... Novartis acquired Tafinlar and Mekinist as part of its asset-swap deal with GlaxoSmithKline (GSK) in 2015.
CHMP round-up. At its meeting last week the CHMP also gave its blessing to the combination of Novartis' Tafinlar (dabrafenib) and Mekinist (trametinib) in BRAF-positive non-small cell lung
Gaining the greenlight were Novartis' Zykadia (ceritinib) for lung cancer and melanoma combination Tafinlar (dabrafenib) and Mekinist (trametinib), and Servier's Lonsurf (trifluridine/tipiracil HCl) for bowel cancer.
NICE's decision hands an advantage in the UK market to Novartis' similar combination of MEK inhibitor Mekinist (trametinib) and BRAF inhibitor Tafinlar (dabrafenib), a duo which was acquired from GlaxoSmithKline ... The list price for a 28-day course of
The four new drugs added to the CDF are Novartis' Zykadia (ceritinib) for lung cancer and melanoma combination Tafinlar (dabrafenib) and Mekinist (trametinib), and Servier's Lonsurf (trifluridine/tipiracil HCl) for
More from news
Approximately 10 fully matching, plus 34 partially matching documents found.
GSK's recently approved MEK inhibitor Mekinist and BRAF inhibitor Tafinlar will position Novartis to become a leader in the potential blockbuster market for metastatic melanoma, neglected by their current portfolio.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...